海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2015年
10期
1427-1430
,共4页
膀胱癌%免疫调节剂%粘附分子%蛋白酶
膀胱癌%免疫調節劑%粘附分子%蛋白酶
방광암%면역조절제%점부분자%단백매
Bladder cancer%Immunomodulators%Adhesion molecules%Protease
目的：分析丝裂霉素、吡柔比星和免疫调节剂联合灌注对膀胱癌患者血清及冲洗液中粘附分子、蛋白酶表达的影响。方法选取2012年10月至2014年10月间在本院接受经尿道膀胱肿瘤电切术(TURBT)治疗的非肌性浸润性膀胱癌患者86例，其中接受丝裂霉素、吡柔比星膀胱灌注治疗者(对照组)和接受丝裂霉素、吡柔比星和免疫调节剂联合灌注治疗者(观察组)各43例。检测两组患者治疗后的血清及冲洗液中的粘附分子、蛋白酶表达情况。结果(1)血清粘附分子：观察组血清细胞粘附分子(CD44v6)、E-钙黏素(E-cadherin)、肝细胞粘附分子(hepaCAM)水平高于对照组，上皮特异性粘附分子(EpCAM)、可溶性细胞间粘附分子-1(sICAM-1)、可溶性血管黏附分子-1(sVCAM-1)水平低于对照组，差异均有统计学意义(P<0.05)；(2)冲洗液粘附分子：观察组冲洗液CD44v6、E-cadherin、hepaCAM水平高于对照组，EpCAM、sICAM-1、sVCAM-1水平低于对照组，差异均有统计学意义(P<0.05)；(3)蛋白酶：观察组血清及冲洗液中基质金属蛋白酶2(MMP2)、基质金属蛋白酶9(MMP9)水平低于对照组，半胱氨酸蛋白酶-8(Caspase-8)水平高于对照组，差异均有统计学意义(P<0.05)。结论丝裂霉素、吡柔比星和免疫调节剂联合灌注可以调节膀胱癌患者的粘附分子及蛋白酶表达，抑制侵袭转移能力、促进肿瘤细胞凋亡。
目的：分析絲裂黴素、吡柔比星和免疫調節劑聯閤灌註對膀胱癌患者血清及遲洗液中粘附分子、蛋白酶錶達的影響。方法選取2012年10月至2014年10月間在本院接受經尿道膀胱腫瘤電切術(TURBT)治療的非肌性浸潤性膀胱癌患者86例，其中接受絲裂黴素、吡柔比星膀胱灌註治療者(對照組)和接受絲裂黴素、吡柔比星和免疫調節劑聯閤灌註治療者(觀察組)各43例。檢測兩組患者治療後的血清及遲洗液中的粘附分子、蛋白酶錶達情況。結果(1)血清粘附分子：觀察組血清細胞粘附分子(CD44v6)、E-鈣黏素(E-cadherin)、肝細胞粘附分子(hepaCAM)水平高于對照組，上皮特異性粘附分子(EpCAM)、可溶性細胞間粘附分子-1(sICAM-1)、可溶性血管黏附分子-1(sVCAM-1)水平低于對照組，差異均有統計學意義(P<0.05)；(2)遲洗液粘附分子：觀察組遲洗液CD44v6、E-cadherin、hepaCAM水平高于對照組，EpCAM、sICAM-1、sVCAM-1水平低于對照組，差異均有統計學意義(P<0.05)；(3)蛋白酶：觀察組血清及遲洗液中基質金屬蛋白酶2(MMP2)、基質金屬蛋白酶9(MMP9)水平低于對照組，半胱氨痠蛋白酶-8(Caspase-8)水平高于對照組，差異均有統計學意義(P<0.05)。結論絲裂黴素、吡柔比星和免疫調節劑聯閤灌註可以調節膀胱癌患者的粘附分子及蛋白酶錶達，抑製侵襲轉移能力、促進腫瘤細胞凋亡。
목적：분석사렬매소、필유비성화면역조절제연합관주대방광암환자혈청급충세액중점부분자、단백매표체적영향。방법선취2012년10월지2014년10월간재본원접수경뇨도방광종류전절술(TURBT)치료적비기성침윤성방광암환자86례，기중접수사렬매소、필유비성방광관주치료자(대조조)화접수사렬매소、필유비성화면역조절제연합관주치료자(관찰조)각43례。검측량조환자치료후적혈청급충세액중적점부분자、단백매표체정황。결과(1)혈청점부분자：관찰조혈청세포점부분자(CD44v6)、E-개점소(E-cadherin)、간세포점부분자(hepaCAM)수평고우대조조，상피특이성점부분자(EpCAM)、가용성세포간점부분자-1(sICAM-1)、가용성혈관점부분자-1(sVCAM-1)수평저우대조조，차이균유통계학의의(P<0.05)；(2)충세액점부분자：관찰조충세액CD44v6、E-cadherin、hepaCAM수평고우대조조，EpCAM、sICAM-1、sVCAM-1수평저우대조조，차이균유통계학의의(P<0.05)；(3)단백매：관찰조혈청급충세액중기질금속단백매2(MMP2)、기질금속단백매9(MMP9)수평저우대조조，반광안산단백매-8(Caspase-8)수평고우대조조，차이균유통계학의의(P<0.05)。결론사렬매소、필유비성화면역조절제연합관주가이조절방광암환자적점부분자급단백매표체，억제침습전이능력、촉진종류세포조망。
Objective To analyze the effect of combined perfusion of mitomycin, pirarubicin, immuno-modulators on the expression of adhesion molecule, protease in serum and rinses of patients with bladder cancer. Methods Eighty-six patients of non-muscle-invasive bladder cancer received transurethral resection of bladder tu-mor (TURBT) in our hospital from October 2012 to October 2014 were selected as study objects, including 43 cases of the control group with mitomycin and pirarubicin for perfusion treatment and 43 cases of the observation group with mitomycin, pirarubicin combined with immunomodulators for perfusion treatment. The expression of adhesion molecules, protease in serum and rinses were detected after treatment. Results (1) In serum, CD44v6, E-cadherin, hepaCAM levels in the observation group were significantly higher than those in the control group, while EpCAM, sI-CAM-1, sVCAM 1 levels in the observation group were significantly lower. (2) In rinses, CD44v6, E-cadherin, hepaCAM levels in the observation group were significantly higher than those in the control group, while EpCAM, sI-CAM-1, sVCAM-1 levels in the observation group were significantly lower. (3) For protease, MMP-2, MMP-9 lev-els in serum and rinses of the observation group were significantly lower than those in the control group, while Cas-pase-8 level of the observation group was significantly higher. Conclusion Combined perfusion of mitomycin, pira-rubicin immunomodulators can adjust the expression of adhesion molecules and protease in patients with bladder can-cer, inhibit invasion and metastasis ability, and promote apoptosis of tumor cells.
